Correction to: Cell. Mol. Life Sci. (2012) 69:3665–3681
10.1007/s00018-012-1045-y.
In this article Fig(s) 7 and 8 appeared incorrectly and have now been corrected in the original publication. For completeness and transparency, the old incorrect versions are displayed below.
Incorrect version of Fig. 7.
Figure 7 increased CTF-β and Aβ trimeric forms in the cortex of MT1 + 2 null males. a, b Representative WB band pattern obtained with 6E10 antibody in total cortical homogenates and fraction C membrane-associated protein enriched fraction), respectively, of male mice. Apart from the specific bands mentioned in Fig. 6, a 14-kDa band, that by its size could represent a trimer of Aβ, was also quantified. MT1 + 2 deficiency in APP+ male mice significantly increased CTF-β and putative Aβ trimer levels in total cortical homogenates (c), and Aβ trimer levels in Fraction C (d). Analysis of female mice total cortical homogenates (e) showed no differences between APP+ genotypes, while in the extracellular protein enriched fraction (f) the 14-kDa band was significantly decreased by MT1 + 2 deficiency. Data represents mean ± SEM (n = 8–13). Plus, p at least ≤0.03 versus APPWT mice.
Corrected version of Fig. 7.
Figure 7 Increased CTF-β and Aβ trimeric forms in the cortex of MT1 + 2 null males. a, b Representative WB band pattern obtained with 6E10 antibody in total cortical homogenates and fraction C membrane-associated protein enriched fraction), respectively, of male mice. Apart from the specific bands mentioned in Fig. 6, a 14-kDa band, that by its size could represent a trimer of Aβ, was also quantified. MT1 ?+ 2 deficiency in APP+ male mice significantly increased CTF-β and putative Aβ trimer levels in total cortical homogenates (c), and Aβ trimer levels in Fraction C (d). Analysis of female mice total cortical homogenates (e) showed no differences between APP+ genotypes, while in the extracellular protein enriched fraction (f) the 14-kDa band was significantly decreased by MT1 + 2 deficiency. Data represents mean ± SEM (n = 8–13). Plus, p at least ≤0.03 versus APPWT mice
Incorrect version of Fig. 8.
Figure 8 APP-induced microgliosis is prevented by MT1 + 2 absence in males. Total cortex and hippocampus homogenates were assayed by WB. a Representative WB obtained with anti-GFAP and anti-Iba1 antibodies in cortex; anti-actin antibodies were used for loading controls and data normalization. b APP+ males showed significantly higher GFAP levels (reflecting astrocytosis) than APP- genotypes in both hippocampal (left) and cortical (right) homogenates. However, no effect due to MT1 + 2 absence was observed in GFAP levels in none of the regions assessed. c Similarly to astrocytosis, Iba1 levels were also increased by hAPP presence compared to controls (reflecting microgliosis), but in this case, MT1 + 2 deficiency significantly prevented this effect. Data represents mean ± SEM (n = 9) and was analyzed using GLZ with APP and MT deficiency as main factors. Filled diamond, p ≤ 0.001 versus APP-; spade, p ≤ 0.04 significant interaction between factors
Corrected version of Fig. 8.
Figure 8 APP-induced microgliosis is prevented by MT1 + 2 absence in males. Total cortex and hippocampus homogenates were assayed by WB. a Representative WB obtained with anti-GFAP and anti-Iba1 antibodies in cortex; anti-actin antibodies were used for loading controls and data normalization. b APP+ males showed significantly higher GFAP levels (reflecting astrocytosis) than APP- genotypes in both hippocampal (left) and cortical (right) homogenates. However, no effect due to MT1 + 2 absence was observed in GFAP levels in none of the regions assessed. c Similarly to astrocytosis, Iba1 levels were also increased by hAPP presence compared to controls (reflecting microgliosis), but in this case, MT1 + 2 deficiency significantly prevented this effect. Data represents mean ± SEM (n = 9) and was analyzed using GLZ with APP and MT deficiency as main factors. Filled diamond, p B≤ 0.001 versus APP-; spade, p ≤ 0.04 significant interaction between factors.
The original article has been corrected.
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary information files.
Declarations
Competing interest
AB holds shares in Cogitate, Ltd, Alterity Ltd and has a profit share arrangement with Collaborative Medicinal Development Pty Ltd. PA holds shares in Alterity Therapeutics.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this published article and its supplementary information files.